Skip to content

Acupuncture Combined With Nimodipine for Prevention of Post-stroke Dementia

Acupuncture Combined With Nimodipine for Prevention of Post-stroke Dementia:a Randomized Controlled Trial

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06007573
Enrollment
40
Registered
2023-08-23
Start date
2021-02-01
Completion date
2023-08-15
Last updated
2023-08-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Post-stroke Dementia

Keywords

randomized controlled trial, post-stroke dementia, Acupuncture, nimodipine

Brief summary

To observe the clinical efficacy of TCM acupuncture combined with western medicine nimodipine for prevention of post-stroke dementia by comparing with clinical conventional treatment methods.

Interventions

DRUGThe control group received oral nimodipine tablets

The control group received oral nimodipine tablets

Sponsors

Department of acupuncture and massage, Nanling Hospital of traditional Chinese Medicine, Nanling County, Wuhu City, Anhui Province
CollaboratorUNKNOWN
Yuzhen Pan
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
40 Years to 85 Years
Healthy volunteers
No

Inclusion criteria

1. Definite ischemic stroke or hemorrhagic stroke confirmed by head CT / MRI examination 2. Memory or cognitive and executive dysfunction. Cognitive dysfunction will be determined after the mini mental state evaluation (MMSE) score 3. Age limited to 40-85 years, irrespective of gender 4. Stable condition, clear consciousness, no aphasia, oral medication available 5. No major comorbidity, no major depression 6. Consent and signed patient informed consent

Exclusion criteria

1. Had serious medical conditions, such as heart, liver, kidney, or endocrine disease 2. Aphasia or hearing impairment 3. Participants in other clinical trials 4. Patients currently on medication to improve cognitive function

Design outcomes

Primary

MeasureTime frame
Response Rate24 weeks

Secondary

MeasureTime frame
Hasegawa Dementia Scale24 weeks
Montreal Cognitive Assessment24 weeks

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026